IP Library Granted Patent US 7,112,565
Granted Patent B2
US 7,112,565 · App. 10/772,281 · Granted Sep 26, 2006

Stabilized pharmaceutical composition in lyophilized form

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,112,565
App. No.
10/772,281
Granted
Sep 26, 2006
Kind
B2
Abstract

A stabilized pharmaceutical composition in lyophilized form comprising: a cyclic polypeptide compound represented by the general formula (I): wherein R 1 is a hydrogen atom or an acyl group and R 2 and R 3 are, the same or different, a hydrogen atom or a hydroxyl group, or a salt thereof and the stabilizer.

Claims (33)

1. A stabilized pharmaceutical composition in lyophilized form which comprises a cyclic polypeptide compound of the general formula (I):

wherein R 1 is a hydrogen atom or an acyl group and R 2 and R 3 are, the same or different, a hydrogen atom or a hydroxyl group; or its pharmaceutically acceptable salt; and

one or more compound(s) selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride.

2. The composition according to claim 1 in which R 1 is represented by the formula:

and R 2 and R 3 are hydroxy groups.

3. The composition according to claim 1 , wherein said compound is a disaccharide.

4. The composition according to claim 1 , wherein said compound is maltose or sucrose.

5. The composition according to claim 1 , wherein said compound is lactose.

6. The composition according to claim 1 , which contains 0.4 to 50 parts by weight of said compound(s) with respect to one part by weight of the cyclic polypeptide compound or its pharmaceutically acceptable salt.

7. The composition according to claim 1 , which contains 0.1 to 400 mg of the cyclic polypeptide compound or its pharmaceutically acceptable salt in a single unit dose.

8. The composition according to claim 1 prepared by:

dissolving the cyclic polypeptide compound (I) or its pharmaceutically acceptable salt, the said compound(s), and optionally a pH adjustor, in a purified water and

lyophilizing the solution.

9. The composition of claim 1 which when dissolved in purified water, gives a solution of pH 4.0 to 7.5.

10. The composition of claim 1 which contains 3.4% or less by weight of water.

11. A method for preparing a stabilized pharmaceutical composition comprising:

dissolving a cyclic polypeptide compound of the general formula (I):

wherein R 1 is a hydrogen atom or an acyl group and R 2 and R 3 are, the same or different, a hydrogen atom or a hydroxyl group, or its pharmaceutically acceptable salt and

one or more compounds selected from the group consisting of a polysaccharide, a disaccharide and sodium chloride in water, and optional a pH adjustor, and

lyophilizing the solution.

12. An injection preparation prepared by dissolving the composition of claim 1 in isotonic sodium chloride solution.

13. A commercial package comprising:

the pharmaceutical composition of claim 1 and written instructions for use thereof.

14. The composition of claim 1 , wherein said compound is a polysaccharide.

15. The composition of claim 1 , wherein said compound is sodium chloride.

16. The composition of claim 1 , further comprising a pH adjustor.

17. The composition of claim 16 , wherein the pH adjustor is acidic.

18. The composition of claim 16 , wherein the pH adjustor is basic.

19. An aqueous composition comprising the composition of claim 1 and water.

20. The aqueous composition of claim 19 , wherein the water is present in an isotonic sodium chloride solution.

21. The aqueous composition of claim 19 , wherein the water consists essentially of purified water.

22. A method for treating a fungal disease comprising administering an effective amount of the composition of claim 1 to a subject in need thereof.

23. The method of claim 22 , wherein said disease is selected from the group consisting of dermatophytosis, pityriasis versicolor, candidiasis, cryptococcosis, geotrichosis, trichosporosis, aspergillosis, penicilliosis, fusariosis, zygomycosis, sporortrichosis, chromomycosis, coccidioidomycosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, pseudallescheriosis, mycetoma, mycotic keratitis, otomycosis and pneumocystosis.

Assignments (1)
MERGER Recorded Dec 12, 2005
From: FUJISAWA PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 017073/0257 →